Publication | Closed Access

Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma

Neoadjuvant TherapyMedicineImmunologyImmune Checkpoint InhibitorRecurrent/metastatic HeadHead And Neck CancerCancer TreatmentNeck OncologyImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentResponse Rates